Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 5, 2010, Pages 673-679

  Movsas, Benjamin ^a   Langer, Corey J ^b   Ross, Helen J ^c   Wang, Luhua ^d   Jotte, Robert M ^e   Feigenberg, Steve ^f   Xu, Feng ^g   Huang, Chao H ^h   Monberg, Matthew J ⁱ   Obasaju, Coleman K ⁱ  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MAYO CLINIC   (United States)

^d CANCER HOSPITAL   (China)

^e Rocky Mountain Cancer Center   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g SICHUAN UNIVERSITY   (China)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ Lilly USA   (United States)

Author keywords

Consolidation; Docetaxel; Gemcitabine; NSCLC; Stage IIIA B

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER FATIGUE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

EID: 77951880999     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d60e8f     Document Type: Article

References (24)

1. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute, 2007.
2. Ademuyiwa FO, Johnson CS, White AS, et al. Prognostic factors in stage III non-small-cell lung cancer. Clin Lung Cancer 2007;8:478-482.
3. Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol 2008;3:917-928.
4. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158. (Pubitemid 24026882)
5. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995;13: 452-458.
6. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-1070.
7. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
8. Curran W, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stagte III NSCLC: RTOG 9410 (abstract). J Clin Oncol 2003;22:2499.
9. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon- Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo- Cancerologie NPC 95-01 Study. J Clin Oncol 2005;23:5910-5917.
10. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
11. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98.
12. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004-2010.
13. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880 -1892.
14. Kroep JR, Giaccone G, Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 1999;17:2190-2197.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
16. NCI Common Toxicity Criteria Version 2.0. Cancer Therapy Evaluation Program. 1999.
17. Therasse P, Arbuck S, Eisenhauer E. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
19. Kelly K, Chansky K, Gaspar LE, et al. Updated analysis of SWOG 0023: a randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer (abstract). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I;23:7513.
20. Kelly K, Gaspar LE, Chansky K, et al. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III nonsmall cell lung cancer (abstract). J Clin Oncol 2005 ASCO Annual Meeting Proceedings Part I;23:7058.
21. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell Lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-5760.
22. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000;18:131-135.
23. Chemotherapy and radiation in treating patients with stage 3 non-small cell lung cancer. Available at: http://clinicaltrials.gov/ct2/show/ NCT00686959?state1-PA%3AAU%3ATA&rank-41. Accessed December 8, 2008.
24. Ciuleanu T, Brodowicz T, Belani C, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study in NSCLC (abstract). J Clin Oncol 2008 ASCO Annual Meeting Proceedings Part I; 26(Suppl 15):8011.